The stock, which is down more than 61% in 2025, sold off after reporting a Q3 EPS beat missing on revenue expectations.
Get insights from Vertex Pharmaceuticals' Q3 2025 earnings call—revenue growth, pipeline milestones, and outlook for ALYFTREK, CASGEVY, and JOURNAVX.
Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...
There are many purposes that spots and stripes serve in nature, but how they form has been more of a mystery to scientists.
Investor's Business Daily on MSN
Vertex Pharma's Mixed Quarter: How Legacy Products Drove Its Beat
Vertex stock dipped late Monday on a mixed third-quarter report, with the lion's share of its sales beat coming from its ...
In the U.S., revenue climbed 15%, to $1.98 billion, helped by strong demand and higher pricing for its cystic-fibrosis drugs, the company said. Its Casgevy and Journavx drugs, which treat severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback